drugset / Trial / NCT03659929

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929

Phase 3 Completed 320 enrolled Arbor Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)

Timeline

Start
2018-09-18
Primary completion
2019-04-12
Completion
2019-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphetamine Unknown 20 mg
Subject Amphetamine Unknown 40 mg